AKLI Stock Price, Akili Inc Quote, Chart

Market Summary

USD0.39+0.16

Delayedas of 30 Apr 2024, 01:08 pm

69.57%

AKLI Stock Price

View Fullscreen

AKLI RSI Chart

AKLI Valuation

Market Cap

18.1M

Price/Earnings (Trailing)

-0.3

Price/Sales (Trailing)

10.76

EV/EBITDA

1.01

Price/Free Cashflow

-0.31

AKLI Price/Sales (Trailing)

AKLI Profitability

Operating Margin

51.19%

EBT Margin

-3542.31%

Return on Equity

-101.64%

Return on Assets

-74.01%

Free Cashflow Yield

-320.57%

AKLI Fundamentals

AKLI Revenue

Revenue (TTM)

1.7M

AKLI Earnings

Earnings (TTM)

-59.5M

Earnings Growth (Yr)

33.71%

Earnings Growth (Qtr)

29.79%

Breaking Down AKLI Revenue

52 Week Range

0.48

(Low)(High)

Last 30 days

-20.7%

Last 90 days

-14.8%

How does AKLI drawdown profile look like?

AKLI Financial Health

Current Ratio

6.02

AKLI Investor Care

Shares Dilution (1Y)

0.52%

Diluted EPS (TTM)

-0.76

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	774.7K	1.2M	0	1.7M
2022	484.3K	430.5K	376.8K	323.0K
2021	0	2.8M	1.7M	538.0K
2020	0	0	0	3.9M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Akili Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 10, 2024	franklin matthew	sold (taxes)	-549	0.34	-1,615	president & ceo
Mar 10, 2024	martucci walter edward ii	sold (taxes)	-883	0.34	-2,599	-
Mar 10, 2024	studer jacqueline	sold (taxes)	-350	0.34	-1,032	chief legal officer
Dec 07, 2023	shanbhag santosh	acquired	-	-	69,750	chief financial officer
Dec 07, 2023	studer jacqueline	acquired	-	-	69,750	chief legal officer
Nov 02, 2023	martucci walter edward ii	sold (taxes)	-2,091	0.3918	-5,337	-
Nov 02, 2023	shanbhag santosh	sold (taxes)	-379	0.3918	-969	chief financial officer
Nov 02, 2023	studer jacqueline	sold (taxes)	-720	0.3918	-1,840	chief legal officer
Oct 05, 2023	martucci walter edward ii	back to issuer	-	-	-2,241,620	-
Sep 11, 2023	franklin matthew	sold	-1,814	1.05	-1,728	president & coo

Which funds bought or sold AKLI recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 26, 2024	YHB Investment Advisors, Inc.	reduced	-76.65	-44,437	7,162	-%
Apr 25, 2024	SIMPLEX TRADING, LLC	added	308,000	-	-	-%
Apr 22, 2024	Raymond James Financial Services Advisors, Inc.	unchanged	-	-2,458	3,605	-%
Mar 11, 2024	VANGUARD GROUP INC	reduced	-1.77	-7,268	49,378	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	sold off	-100	-6,612	-	-%
Feb 16, 2024	HARBOUR INVESTMENTS, INC.	unchanged	-	-18.00	145	-%
Feb 14, 2024	BANK OF AMERICA CORP /DE/	reduced	-99.86	-13,747	18.00	-%
Feb 14, 2024	Temasek Holdings (Private) Ltd	unchanged	-	-711,264	5,606,090	0.03%
Feb 14, 2024	Royal Bank of Canada	added	4.54	-	1,000	-%
Feb 14, 2024	SUSQUEHANNA INTERNATIONAL GROUP, LLP	added	217	10,311	16,315	-%

Are Funds Buying or Selling AKLI?

Are funds buying AKLI calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own AKLI

No. of Funds

Unveiling Akili Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	cowen aaron	6.0%	4,699,219	SC 13G/A
Feb 12, 2024	neuberger berman group llc	7.38%	5,776,784	SC 13G
Jan 29, 2024	baillie gifford & co	5.96%	4,665,795	SC 13G/A

Recent SEC filings of Akili Inc

View All Filings

Date Filed	Form Type	Document
Apr 23, 2024	8-K	Current Report
Mar 12, 2024	4	Insider Trading
Mar 12, 2024	4	Insider Trading
Mar 12, 2024	4	Insider Trading
Mar 06, 2024	ARS	ARS
Mar 06, 2024	DEF 14A	DEF 14A
Mar 06, 2024	DEFA14A	DEFA14A
Feb 29, 2024	S-8	Employee Benefits Plan
Feb 29, 2024	10-K	Annual Report
Feb 26, 2024	8-K	Current Report

Peers (Alternatives to Akili Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
UNH	450.9B	371.6B	-1.15%	-0.62%	20.14	1.21	14.64%	11.24%
CI	104.2B	195.3B	-1.86%	40.72%	19.4	0.53	8.17%	-20.79%
CVS	84.9B	357.8B	-15.43%	-7.99%	10.16	0.24	10.95%	93.52%
HCA	82.4B	65.0B	-6.63%	8.38%	15.71	1.27	7.86%	-7.11%
CNC	39.5B	155.5B	-5.93%	7.11%	14.44	0.25	6.34%	84.42%
DVA	12.1B	12.1B	0.07%	52.88%	17.52	1	4.57%	23.40%
UHS	11.7B	14.3B	-7.31%	12.48%	16.33	0.82	6.59%	6.24%
MID-CAP
CHE	8.6B	2.3B	-11.65%	2.88%	30.26	3.74	5.96%	18.29%
ACHC	6.9B	2.9B	-5.81%	3.22%	-317.8	2.35	12.20%	-107.93%
AMN	2.3B	3.8B	-4.85%	-31.12%	10.69	0.59	-27.73%	-52.50%
AMEH	2.1B	1.4B	-9.84%	6.68%	34.56	1.51	21.19%	34.42%
SMALL-CAP
ADUS	1.5B	1.1B	-8.86%	15.22%	24.45	1.44	11.31%	35.83%
BKD	1.3B	3.0B	4.54%	61.07%	-6.92	0.43	6.74%	20.73%
BEAT	54.0M	-	-5.96%	-9.29%	-3.69	-	-	-12.94%
AMS	20.6M	21.3M	10.17%	16.91%	38.6	0.96	8.00%	-62.25%

Akili Inc News

Latest updates

Akili Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2020Q4
Revenue	-100.0%	-	114,000	104,400	94,800	85,200	75,600	66,000	79,000	92,000	105,000	-
Cost Of Revenue	68.0%	252,000	150,000	137,000	125,000	123,000	97,000	96,000	112,000	83,000	98,000	-
Gross Profit	1480.6%	497,000	-36,000	-24,000	-14,000	-41,000	-33,000	-30,000	49,000	72,000	7,000	-
Operating Expenses	-20.7%	12,120,000	15,281,000	19,095,000	22,093,000	24,465,000	22,306,000	21,695,000	2,178,252	18,048,000	14,565,000	-
S&GA Expenses	-26.5%	7,824,000	10,648,000	13,011,000	14,451,000	16,911,000	14,948,000	15,391,000	13,993,000	13,292,000	10,526,000	-
R&D Expenses	-7.3%	4,296,000	4,633,000	6,084,000	7,642,000	7,554,000	7,358,000	6,304,000	5,495,000	4,756,000	4,039,000	-
EBITDA Margin	-264.3%	-33.84	20.59	-14.01	-19.05	-24.98	-188	-151	-112	-18.02	-11.17	-6.35
Interest Expenses	-18.3%	519,000	635,000	622,000	618,000	496,000	194,000	176,000	173,000	172,000	39,000	-
Income Taxes	-	37,000	-	-	19,000	-	-	-	-	-	-	-
Earnings Before Taxes	5.7%	-11,094,000	-11,759,000	-20,711,000	-16,796,000	53,236,000	-22,493,000	-21,892,000	-19,611,000	-18,137,000	-14,774,000	-
EBT Margin	-388.2%	-35.42	12.29	-20.94	-24.60	-28.56	-190	-153	-114	-18.47	-11.46	-6.51
Net Income	5.2%	-11,147,000	-11,759,000	-20,711,000	-16,815,000	53,236,000	-22,493,000	-21,892,000	-19,610,000	-18,137,000	-14,774,000	-
Net Income Margin	-389.8%	-35.45	12.23	-21.00	-24.66	-28.56	-190	-153	-114	-18.47	-11.46	-6.51
Free Cashflow	21.1%	-9,143,000	-11,594,000	-19,101,000	-20,959,000	-21,212,000	-19,157,000	-22,235,000	-9,067,976	-7,924,416	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet													(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4
Assets	-13.7%	80.00	93.00	111	125	145	165	55.00	251	81.00	251	174	97.00	20.00
Current Assets	-13.9%	78.00	91.00	109	121	141	161	51.00	1.00	80.00	1.00	0.00	-	19.00
Cash Equivalents	1.8%	75.00	74.00	56.00	88.00	54.00	90.00	41.00	0.00	77.00	1.00	110	-	19.00
Net PPE	5.6%	1.00	1.00	1.00	1.00	1.00	1.00	1.00	-	1.00	-	-	-	1.00
Liabilities	-9.1%	22.00	24.00	29.00	32.00	34.00	41.00	30.00	13.00	15.00	8.00	-	-	8.00
Current Liabilities	-0.6%	13.00	13.00	13.00	11.00	14.00	13.00	11.00	6.00	8.00	0.00	1.00	0.00	4.00
Shareholder's Equity	-15.3%	59.00	69.00	83.00	92.00	111	124	-	-	-226	-	0.00	0.00	-
Retained Earnings	-3.9%	-299	-288	-272	-261	-240	-223	-275	-12.68	-226	-6.33	-6.07	-0.01	-114
Additional Paid-In Capital	0.2%	358	358	356	353	351	347	-	-	-	-	-	0.00	10.00
Shares Outstanding	0.1%	78.00	78.00	78.00	78.00	78.00	14.00	-	2.00	2.00	1.00	1.00	6.00	1.00
Float	-	-	-	67.00	-	-	-	247	-	-	-	251	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)														(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2021Q1	2020Q4
Cashflow From Operations	49.4%	-9,137	-18,045	-11,587	-19,098	-20,959	-21,183	-19,154	-22,225	-9,055	-7,917	-19.84	-	-	-
Share Based Compensation	-66.4%	556	1,655	1,837	2,759	2,117	3,153	1,969	2,070	1,365	1,748	-	-	-	-
Cashflow From Investing	-67.0%	12,370	37,497	-19,369	52,915	-14,581	-61,648	9,997	-14,984	-6.00	-377	-	-	-	-
Cashflow From Financing	1.9%	-1,882	-1,919	-647	-45.00	-24.00	131,854	10,041	64.00	45.00	125,786	243	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

AKLI Income Statement

2023-12-31

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Revenues	$ 1,678	$ 323
Cost of revenues	819	441
Gross profit (loss)	859	(118)
Operating expenses:
Research and development	19,925	28,858
Selling, general and administrative	45,419	61,701
Total operating expenses	65,344	90,559
Operating loss	(64,485)	(90,677)
Other income (expense):
Other income	4,040	1,482
Interest expense	(2,358)	(1,484)
Change in estimated fair value of earn-out liabilities	3,363	82,734
Total other income	5,045	82,732
Loss before income taxes	(59,440)	(7,945)
Income tax expense	(53)	(19)
Net loss	(59,493)	(7,964)
Unrealized gain (loss) on short-term investments	21	(21)
Comprehensive loss	(59,472)	(7,985)
Net loss	(59,493)	(7,964)
Dividends on Series D convertible preferred stock		(7,383)
Redemption value of Series D convertible preferred stock	0	(3,692)
Net loss attributable to common stockholders - basic	$ (59,493)	$ (19,039)
Net loss per share attributable to common stockholders - basic	$ (0.76)	$ (0.64)
Net loss per share attributable to common stockholders - diluted	$ (0.76)	$ (0.64)
Weighted average common stock outstanding - basic	78,197,107	29,878,041
Weighted average common shares outstanding - diluted	78,197,107	29,878,041

AKLI Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 75,150	$ 54,097
Restricted cash	305	305
Short-term investments		82,034
Accounts receivable	300	41
Prepaid expenses and other current assets	2,275	4,565
Total current assets	78,030	141,042
Property and equipment, net	680	919
Operating lease right-of-use asset	1,577	2,596
Prepaid expenses and other long-term assets	96
Total assets	80,383	144,557
Current liabilities:
Accounts payable	1,285	2,681
Accrued expenses and other current liabilities	3,326	5,616
Deferred revenue	100	106
Operating lease liability	756	826
Note payable, short term	7,500	4,375
Total current liabilities	12,967	13,604
Note payable, long term	3,445	10,442
Operating lease liability, net of current portion	1,730	2,485
Corporate bond, net of bond discount	2,054	1,834
Earn-out liabilities	1,632	5,513
Other long-term liabilities	23
Total liabilities	21,851	33,878
Commitments and contingencies
Stockholders' equity
Common stock, $0.0001 par value: 1,000,000,000 shares authorized; 78,356,527 and 78,022,924 shares issued and outstanding at December 31, 2023 and 2022, respectively	8	8
Additional paid-in capital	358,305	350,980
Accumulated deficit	(299,781)	(240,288)
Accumulated other comprehensive loss		(21)
Total stockholders' equity	58,532	110,679
Total liabilities and stockholders' equity	$ 80,383	$ 144,557

About Akili Inc

Akili, Inc., a digital medicine company, develops cognitive treatments through game-changing technologies. The company provides EndeavorRx, a computer-based testing for cognitive dysfunction across several neurology and psychiatry indications, including attention-deficit hyperactivity disorder, depressive disorder, autism spectrum disorder, multiple sclerosis, and other neuroinflammatory diseases. It offers selective stimulus management engine mechanism to activate the fronto-parietal cortex area in the brain; body brain trainer for attention, impulsivity, working memory, and goal management; and spatial navigation engine for spatial navigation, memory, and planning and organization. Akili, Inc. was founded in 2011 and is headquartered in Boston, Massachusetts.

CEO	Dr. Walter Edward Martucci II, Ph.D.
WEBSITE	akiliinteractive.com
INDUSTRY	Healthcare Plans
EMPLOYEES	111

Akili Inc Frequently Asked Questions

What is the ticker symbol for Akili Inc? What does AKLI stand for in stocks?

AKLI is the stock ticker symbol of Akili Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Akili Inc (AKLI)?

As of Mon Apr 29 2024, market cap of Akili Inc is 18.06 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AKLI stock?

You can check AKLI's fair value in chart for subscribers.

What is the fair value of AKLI stock?

You can check AKLI's fair value in chart for subscribers. The fair value of Akili Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Akili Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AKLI so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Akili Inc a good stock to buy?

The fair value guage provides a quick view whether AKLI is over valued or under valued. Whether Akili Inc is cheap or expensive depends on the assumptions which impact Akili Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AKLI.

What is Akili Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Apr 29 2024, AKLI's PE ratio (Price to Earnings) is -0.3 and Price to Sales (PS) ratio is 10.76. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AKLI PE ratio will change depending on the future growth rate expectations of investors.